Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BEYONDSPRING INC.

(BYSI)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
0.5963 USD   -1.05%
11/25Sector Update: Health Care Stocks Flat To Higher Premarket Friday
MT
11/25BeyondSpring Receives Non-Compliance Notice From Nasdaq
MT
11/24BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements, November 23, 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evercore ISI Adjusts BeyondSpring PT to $25 From $95, Maintains Outperform Rating

12/02/2021 | 01:07pm EST


ę MT Newswires 2021
All news about BEYONDSPRING INC.
11/25Sector Update: Health Care Stocks Flat To Higher Premarket Friday
MT
11/25BeyondSpring Receives Non-Compliance Notice From Nasdaq
MT
11/24BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements, November ..
AQ
11/23BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
AQ
09/19BeyondSpring Inc.(NasdaqCM:BYSI) dropped from S&P Global BMI ..
CI
09/13BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Mon..
AQ
09/13BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyt..
CI
08/31North American Morning Briefing: Stocks Look to -2-
DJ
08/29BeyondSpring Inc. Announces Board Appointments
CI
08/29BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease ..
AQ
More news
Analyst Recommendations on BEYONDSPRING INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -57,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,43x
Yield 2022 -
Capitalization 23,2 M 23,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 19,3x
Nbr of Employees 103
Free-Float 59,4%
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 0,60 $
Average target price 2,30 $
Spread / Average Target 286%
EPS Revisions
Managers and Directors
Lan Huang Chairman & Chief Executive Officer
Elizabeth Adkins Czerepak Chief Financial Officer
Ramon W. Mohanlal Director, Chief Medical Officer, Executive VP-R&D
G. Kenneth Lloyd Chief Scientific Officer
Matthew Kirkby Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BEYONDSPRING INC.-86.84%23
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930